New Patent for Pancreatic Cancer Treatment Using APR-246

Dr. Ali Haider Mohammed Ali Al-Hamar, a researcher from the Biotechnology Research Center at Al-Nahrain University, has obtained a patent titled:
“The Use of APR-246 as a Synergistic Treatment with 5-Fluorouracil to Induce Apoptosis in Pancreatic Cancer Cells.”

This patent holds significant importance in the field of pancreatic cancer treatment, as this type of cancer is among the most lethal due to its resistance to conventional therapies. The drug APR-246 targets the p53 protein, which is mutated in approximately 75% of pancreatic cancer cases, making it a promising target for enhancing treatment efficacy.

Preclinical study results showed that APR-246, when used alone, was effective against both wild-type and mutated pancreatic cancer cells. However, the most remarkable finding was the synergistic effect observed when it was combined with 5-fluorouracil, leading to a boost in treatment effectiveness and induction of cancer cell apoptosis by up to 80%. This breakthrough opens new avenues for reducing chemotherapy doses and minimizing side effects, thereby improving treatment efficacy and patient safety.

This study was the result of a collaborative effort between the researcher from the Biotechnology Research Center and other researchers from the College of Pharmacy at Al-Mustansiriyah University. Moreover, the same research has been published in a prestigious scientific journal specializing in new cancer treatment research, classified within the Q1 category in Scopus and Clarivate rankings.

These findings lay a strong foundation for future preclinical and clinical trials, especially since APR-246 has previously shown success in treating other types of cancer with low side effects.

For more information about the researcher’s biography, visit:
Researcher’s Profile

https://cv.nahrainuniv.edu.iq/en/view/2153

Research Link:
Springer Article

https://link.springer.com/article/10.1007/s10637-023-01380-5